A carregar...
Optimal Sequential Enrichment Designs for Phase II Clinical Trials
In the early phase development of molecularly targeted agents (MTAs), a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup, say marker-positive patients, but there is no adequate evidence to show that the MTA does not work for the other s...
Na minha lista:
| Publicado no: | Stat Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5138118/ https://ncbi.nlm.nih.gov/pubmed/27640874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.7128 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|